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ABSTRACT 
Adrenocarcinoma is an uncontrolled growth of epithelial cells originating in the ducts or breast lobules. EGFR or Epidermal growth factor 
receptor is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular 
milieu to the cell. 45 bisindole-imdazopyridine analogues were obtained from the literature. Free-wilson QSAR studies were erformed on the 
given data set. Compounds were designed on the basis of QSAR studies. Further, Molecular docking studies were performed on the designed 
compounds to check the binding affinity on the protein. After that Drug-likeliness and ADMET studies were performed on the selected 
molecules. The results revealed that the selected analogues can be used against the treatment of adrenocarcinoma.  
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INTRODUCTION  
Carcinomas are a complex form of human tumors 
(approximately 80% of all noncutaneous malignancies) and 
the most dangerous and common carcinoma is 
adenocarcinoma. Glandular or secretory epithelium 
containing any organ, and the most frequent sites including 
lungs, kidney, gastrointestinal tract, breast, and prostate can 
be affected by adenocarcinoma. Carcinomas like breast 
carcinoma is a group of malignant epithelial tumor 
characterized by the invasion of adjacent tissue and a 
marked tendancy to metastasize to distant sites. This is 
critical, as the WHO world cancer report indicates that by 
2020, global cancer rate increase by 50% to 15 million [1,2].  
The mutation and over expression of the epidermal growth 
factor receptor (EGFR) are associated with the development 
of a variety of cancers. EGFR is a protein that is present on 
the surface of both normal cells and cancer cells such as lung 
cancer cells. In the United States, an EGFR mutation is 
present in roughly 15 percent of people with lung cancer, in 
people of Eastern Asian descent though this number 
increases to 35 to 50 percent.[3] Mutations are more common 
in women than in men (42% versus 14%), in patients who 
have never smoked than in patients who have smoked (51% 
versus 10%), and in patients with adenocarcinoma than in 
those with other histologies (40% versus 3%).[4]  EGFR 
mutations were generally assumed to give rise to 
spontaneous kinase activation, eliminating the dependence 
of the cancer mutants on dimerisation for activation[5] 
45 bis-indole-imidazopyridine analogues were obtained 
from the literature. Bis-indole-imidazopyridine nucleus is 
present in many natural products isolated from marine 
sources with broad spectrum of biological activities.[6]  
MATERIALS AND METHDS 
QSAR studies: 
QSAR is performed to co-relate biological properties with 
different substituents in a nucleus. A new series of bisindole-
imidazopyridine analogues (45 molecules) were taken from 
literature survey.  Free-wilson QSAR studies were performed 
on the given data set transferred to VALSTAT program and 
the best QSAR model was selected for study. Compounds 
were designed on the basis of QSAR studies.[7] 
Molecular Docking: 
Molecular docking is performed to study ligand protein 
interactions and predict the biological properties of 
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molecules. There are 20 bisindole-imidazopyridine 
analogues A1-A20 (screened by QSAR analysis), were 
designed. The software used in structure designing of 
molecules are ChemDraw and Chem3D.[8] Protein used for 
the docking study was PDB code : 5HIB, which is EGFR 
kinase domain mutant "TMLR" with a pyrazolopyrimidine 
inhibitor obtained from RCSB PDB.[9] Software used for 
docking studies was Autodock docking 4.2.6. Autodock score 
was generated by default calculation setting in software for 
all analogues. H-bond interactions were observed at 
autodock software after docking studies.[10] 
ADME Studies: 
Absorption, distribution, metabolism and excretion, all 
pharmacokinetic properties of selected 5 analogues were 
performed to co-relate pharmacokinetic properties with 
pharmacodynamic properties of analogues. [11, 12] 
RESULT AND DISCUSSION  
QSAR Analysis: 
Free-Wilson analysis performed on all analogues A1-A20 and 
best model generated by VALSTAT program was selected. 
According to the results obtained, the electron withdrawing 
groups such as methoxy group are most active substituent at 
R1, R2 and R3 positions. This study helped in the designing 
of molecules with more effective biological activity. 
 
 
Table 1: QSAR Results 
Parameter Value 
n  18  
r  0.707822  
r2  0.501012  
variance  0.02939  
Std error  0.171434  
F  53.7887  
Q2  0.922516  
 
Biological activity = [4.89182( ± 0.120595)] +35H 
[0.0918182( ± 0.220959)] +35OMe [0.418182( ± 0.288276)] 
+25OMe[0.451818( ± 0.288276)] 
   
Table 2: All analogues with substituents 
Compound R1 R2 R3 Compound R1 R2 R3 
A1 4H 5-H 5-H A11 3,4-diOMe 5-Br 5-Br 
A2 4H 5-OMe 5-OMe A12 3,4-diOMe 5-CN 5-CN 
A3 4H 5-Br 5-Br A13 4-CF3 5-H 5-H 
A4 4H 5-CN 5-CN A14 4-CF3 5-OMe 5-OMe 
A5 4OMe 5-H 5-H A15 4-CF3 5-Br 5-Br 
A6 4OMe 5-OMe 5-OMe A16 4-CF3 5-CN 5-CN 
A7 4OMe 5-Br 5-Br A17 4-F 5-H 5-H 
A8 4OMe 5-CN 5-CN A18 4-F 5-OMe 5-OMe 
A9 3,4-diOMe 5-H 5-H A19 4-F 5-Br 5-Br 
A10 3,4-diOMe 5-OMe 5-OMe A20 4-F 5-CN 5-CN 
 
 
Bis-indole-imidazopyridine moiety 
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Molecular Docking: 
The Protein used, PDB code 5HIB, it was reported contains a 
co-crystallized ligand name 63M bind to active site with H-
bond interaction with Lys745 and Met793. It was found that 
the scores obtained were higher than the co-crystallized 
ligand . The most active compound A13 having binding with 
Lys745 (fig 1.2). 
 
Table 3: Docking results 
Compound Autodock Score 
A15 -9.4 
A3 -9.2 
A2 -9 
A13 -9 
A14 -9 
63M -6.6 
 
 
 
ADME Studies : 
TABLE 4 : ADME Parameters and results 
Parameters 
Results 
A15 A3 A2 A13 A14 
BBB 14.58 5.17962 0.17972 4.95409 0.578674 
Buffer_solubility_mg_L 6.90151 9216.32 26.5598 75.401 8.41534 
Caco2 55.4643 49.9737 56.4482 35.7488 40.6508 
CYP_2C19_inhibition Non Non Non Non Non 
CYP_2C9_inhibition Inhibitor Non Non Non Non 
HIA 94.994747 95.53804 96.2376 95.5215 96.266776 
MDCK 0.018101 0.156428 2.96545 0.0634228 0.0459559 
Plasma_Protein_Binding 100 100 86.5571 100 89.559723 
Pure water solubility mg/L 0.0001497 0.0932111 7.4954 0.640586 1.26297 
Skin_Permeability -2.47492 -3.13826 -3.69998 -2.33411 -2.68818 
SKlogD_value 7.41626 4.6973 3.40234 5.00846 4.32502 
 
CONCLUSION  
The selected series of compounds on which QSAR and 
molecular docking studies were performed which resulted in 
identification of 5 potential compounds which can be used 
for further in-vitro and in-vivo studies, against the treatment 
of breast cancer. 
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